Study of 18F-NY104 PETCT Imaging and Low-Dose Acetazolamide in Adults with Renal Cell Carcinoma

What this Trial Is About

Researchers are evaluating the accuracy of 18F-NY104 PETCT scans in detecting primary, recurrent, and metastatic lesions in patients with renal cell carcinoma RCC. This study also investigates how a low dose of an oral CAIX inhibitor, Acetazolamide, affects the distribution of 18F-NY104 in tissues, particularly in the stomach and kidneys. RCC is an aggressive kidney cancer with rising incidence, often diagnosed late, making better imaging methods important for early diagnosis and treatment planning. The study uses the radioactive tracer 18F-NY104 labeled with 18FAlF for PETCT imaging. All participants will receive an 18F-NY104 PETCT scan to assess tumor location and progression. This imaging agent targets carbonic anhydrase IX CAIX, which is highly expressed in RCC tumors. The study includes adult patients clinically diagnosed or suspected of RCC or its recurrencemetastasis, with measurable solid lesions. Participants will undergo PETCT scans and clinical assessments during the study. Researchers will measure the standardized uptake value SUV over two years to evaluate the imaging agents performance. Laboratory tests, performance status, and survival expectations will be monitored. The study aims to support better diagnosis and staging of RCC through detailed imaging and tissue distribution analysis of the tracer.

Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma